Mural Oncology Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Mural Oncology Plc (MURA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Mural Oncology Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Mural Oncology Plc | - | - | - | Yes |
| Competitors combined (63) | ||||
| High-Confidence Competitors (21) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MURA Stock Performance relative to its Competitors
MURA Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Spyre Therapeutics Inc | 282.9% | Outperformed |
| 3 | Revolution Medicines Inc | 282.9% | Outperformed |
| 4 | Xencor Inc | 282.9% | Outperformed |
| 5 | Enliven Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Mural Oncology Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Mural Oncology Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Mural Oncology Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Mural Oncology Plc |
35.34 | - |
 Merck and Co Inc |
364,967.20 | 66,569.00 |
 Novartis Ag |
313,777.50 | 56,674.00 |
 Astrazeneca Plc |
288,110.90 | 58,739.00 |
 Pfizer Inc |
166,146.39 | 63,625.00 |
 Bristol myers Squibb Company |
130,221.79 | 50,033.00 |
| SUBTOTAL | 1,389,520.71 | 301,935.04 |
Sign in to see all competitors of Mural Oncology Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Mural Oncology Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Mural Oncology Plc's Competitors Named by the Company
Competitive relationships identified from Mural Oncology Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Instil Bio Inc | Company report | 85% |
| Prime Medicine, Inc. | Company report | 85% |
| Moderna, Inc. | Company report | 85% |
| Capstan Therapeutics Inc. | Company report | 85% |
| Orna Therapeutics, Inc. | Company report | 85% |
| Chongqing Zhifei Biological | Company report | 85% |
| nemvaleukin | Company report | 85% |
| Arrowhead Pharmaceuticals, Inc. | Company report | 85% |
| Hoffmann La Roche Ltd. | Company report | 85% |
| Monte Rosa Therapeutics, Inc. | Company report | 85% |
| Wave Life Sciences Ltd. | Company report | 85% |
| bevacizumab | Company report | 85% |
| Amgen Inc | Company report | 85% |
| Kymera Therapeutics, Inc. | Company report | 85% |
| Icon Genetics | Company report | 85% |
| PARP | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Nurix Therapeutics, Inc. | Company report | 85% |
| China National Biotec | Company report | 85% |
| Cohort 4 of ARTISTRY-6 | Company report | 85% |
| argenx SE | Company report | 85% |
| Vaxart | Company report | 85% |
| pembrolizumab | Company report | 85% |
| Alnylam Pharmaceuticals, Inc. | Company report | 85% |
| Janssen | Company report | 85% |
| Beam Therapeutics Inc. | Company report | 85% |
| iECURE, Inc. | Company report | 85% |
| Tessera Therapeutics, Inc. | Company report | 85% |
| Sonnet | Company report | 85% |
| Intellia Therapeutics, Inc. | Company report | 85% |
| AstraZeneca | Company report | 85% |
| CRISPR Therapeutics AG | Company report | 85% |
| Editas Medicine, Inc. | Company report | 85% |
| Q32 Bio Inc | Company report | 85% |
| Werewolf Therapeutics Inc | Company report | 85% |
| Springworks Therapeutics Inc | Company report | 85% |
| Bnb Plus Corp | Company report | 85% |
| Nuvalent Inc | Company report | 85% |
| Regenxbio Inc | Company report | 85% |
| Sana Biotechnology Inc | Company report | 85% |
| Sangamo Therapeutics Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Mural Oncology Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Mural Oncology Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Protagonist Therapeutics inc | Single reportable segment 100.00 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Mural Oncology Plc.
Mural Oncology Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Mural Oncology Plc | 35 | - | -3,609,061 |
| Merck and Co Inc | 364,967 | 887,587 | 42,267 |
| Novartis Ag | 313,778 | 752,973 | 185,566 |
| Astrazeneca Plc | 288,111 | 706,847 | 123,141 |
| Pfizer Inc | 166,146 | 848,333 | 54,160 |
| Bristol myers Squibb Company | 130,222 | 1,539,477 | 284,338 |
| PEERS TOTAL | 1,389,485 | 861,006 | 101,393 |
Sign in to see all peers for Mural Oncology Plc.
Mural Oncology Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.73 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Mural Oncology Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 490 companies in Mural Oncology Plc's industry classification, broader than the peer set above. Market cap in millions of $.Mural Oncology Plc ranks #0 of 490 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 996, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,270,305 | 23.98 % |
| 2 | Johnson and Johnson | 693,281 | 13.09 % |
| 3 | Abbvie Inc | 521,232 | 9.84 % |
| 4 | Merck and Co Inc | 359,385 | 6.78 % |
| 5 | Novartis Ag | 1,234 | 5.2% |
| 6 | Abbott Laboratories | 1,234 | 5.2% |
| 7 | Novo Nordisk A | 1,234 | 5.2% |
| 8 | Pfizer Inc | 1,234 | 5.2% |
| 9 | Astrazeneca Plc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Mural Oncology Plc | 35 | 0.00 % |
Market cap and industry share for the rest of Mural Oncology Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-12-04.
Mural Oncology Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (447 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 26.3x | - |
| EV / EBITDA | - | 15.1x | - |
| P/B | 0.4x | 4.2x | -3.8x |
| Return on Equity | -131.47 % | industry aggregate | -149.06 % |
| Return on Invested Capital | -67.53 % | -9.73 % (avg) | -57.80 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Mural Oncology Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 996 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Mural Oncology Plc's dedicated Suppliers and Customers pages, not here.
Mural Oncology Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 149.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (48.40 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-37.4% annualized).
Methodology: see Methodology: SWOT Analysis.
Mural Oncology Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Mural Oncology Plc | 4.06 | 4.69 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
Sign in to see all peers for Mural Oncology Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Mural Oncology Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Mural Oncology Plc | Q3 2025 | - | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| PEERS TOTAL | +8.3 % | -1.4 % |
Sign in to see all peers for Mural Oncology Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Mural Oncology Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Mural Oncology Plc | Q3 2025 | - | - |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
Sign in to see all peers for Mural Oncology Plc.
Mural Oncology Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Mural Oncology Plc | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
Sign in to see all peers for Mural Oncology Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Mural Oncology Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Mural Oncology Plc | - | - |
| Merck and Co Inc | 119.16 | 5.48 |
| Novartis Ag | 22.44 | 5.54 |
| Astrazeneca Plc | 28.20 | 4.90 |
| Pfizer Inc | 41.12 | 2.61 |
| Bristol myers Squibb Company | 14.06 | 2.60 |
| PEERS AVERAGE | 39.21 | 4.60 |
Sign in to see all peers for Mural Oncology Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.